97% of Evaluated Drugs are Overpriced, According to ICER
2018 was not a good year for biopharma manufacturers, based on the Institute for Clinical and Economic Review’s (ICER) evaluation of interventions across various disease areas. Seemingly every month, ICER generated negative press for the biopharma industry. Headlines read:
Five Ways to Use Early-Stage Models to Support Your Drug’s Value Proposition
Written by Jennifer Benner. In my previous post, I explored the differences between early- and late-stage economic modeling, including a discussion of the benefits of using early-stage models. In this post, I will examine 5 ways that utilizing early-stage models can benefit drug manufacturers and help produce more efficient, cost-effective drug[…]
How to Predict if a Drug will be Cost-Effective: A Case for Early-Stage Modeling
Written by Jennifer Benner. Wouldn’t it be nice if there were a crystal ball that could predict, during the very early stages of drug development, whether a new medication would represent good value for money at its intended launch price? Or which efficacy targets it needed to hit in order to remain cost-effective? Or what an assessment by the[…]
Do Research Groups Align on the Value of an Intervention? A Prelude to our ISPOR Barcelona Presentation
Do Research Groups Align on the Value of an Intervention? A Prelude to our ISPOR Barcelona Presentation By Matthew Sussman
Big Changes for HEOR in 2017
As we make our way through the first quarter of 2017, there are a lot of exciting changes happening in the field of health economics and outcomes research (HEOR) that may have important implications for how researchers generate and disseminate evidence.